Herzuma® (biosimilar trastuzumab) is a monoclonal antibody (mAb) biosimilar in oncology approved by the European Medicines Agency (EMA). Herzuma® is indicated for the treatment of adult patients with early breast cancer, metastatic breast cancer, and metastatic gastric cancer.*

Herzuma®▼ is subject to additional monitoring

If you experience any side effects when taking Herzuma®▼ or any other medicine, talk to your doctor, pharmacist or nurse. This includes possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.


  •  

    Herzuma® is approved for the treatment of
    Early Breast Cancer.
    Learn More
  •  

    Herzuma® is approved for the treatment of Metastatic Breast Cancer (breast cancer that has spread beyond the original tumour).
    Learn More
  •  

    Herzuma® is approved for the treatment of Metastatic Gastric Cancer (gastric cancer that has spread beyond the original tumour).
    Learn More